Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
Status:
Withdrawn
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This study has two portions. The main goal of the Phase Ib portion of this research study is
to see at what time Yttrium-90 (Y-90) radioembolization therapy and nivolumab can safely be
given to patients without having too many side effects. Other purposes of this research study
will be to study any tumor responses.
The Phase II portion of the study will test how many patients show shrinkage in their tumor
with this combination of medicines and what changes occur inside the cancer cells and blood
cells after treatment. The study team will pick the part of the study each subject
participates in.
Y-90 radioembolization therapy is minimally invasive procedure that combines two types of
therapy (embolization which blocks certain blood vessels, and radiation therapy, which kills
cancer cells) to treat cancer tumors in the liver. This works with tiny glass or resin beads
filled with the radioactive isotope yttrium-90 (Y-90). They are placed inside the blood
vessels that feed the tumor in the liver. This blocks the supply of blood to the cancer cells
and delivers a high dose of radiation to the tumor while sparing normal tissue.
Nivolumab is an FDA approved medicine that is used for the treatment of different types of
cancers and metastases (second growths from cancer).